DrugBiological
Briquilimab clinical trials
Also written JSP191.
- studies test it
- 11
- open now
- 1
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the briquilimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 4
Jasper Therapeutics, Inc. (7) · National Heart, Lung, and Blood Institute (NHLBI) (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Porteus, Matthew, MD (1)
Often tested with
Tested in the same studies.
Sirolimus (2) · Abatacept (1) · Cyclophosphamide (1) · Hydroxyurea (1) · Filgrastim (1) · Alemtuzumab (1) · Plerixafor (1)
Studies
Open first, then newest update. How each study uses briquilimab is read from its arms, and is right about nine times in ten.
Testing it · 11
- Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing BriquilimabRecruitingPhase 1/2Porteus, Matthew, MDNCT04784052Written as JSP191
- JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell TransplantationCompletedPhase 1Jasper Therapeutics, Inc.NCT04429191Written as Humanized anti-CD117 Monoclonal Antibody (JSP191)
- Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)Active, not recruitingEarly Phase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05600907Written as JSP191
- Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)CompletedPhase 1/2Jasper Therapeutics, Inc.NCT06162728Written as Briquilimab
- A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsTerminatedPhase 2Jasper Therapeutics, Inc.NCT06736262Written as Briquilimab
- Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ FunctionActive, not recruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT06145282Written as Briquilimab
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaActive, not recruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT05357482Written as briquilimab
- A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- AntihistaminesTerminatedPhase 1/2Jasper Therapeutics, Inc.NCT06353971Written as Briquilimab
- A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic AsthmaTerminatedPhase 1Jasper Therapeutics, Inc.NCT06592768Written as Briquilimab
- JSP191 Antibody Targeting Conditioning in SCID PatientsTerminatedPhase 1/2Jasper Therapeutics, Inc.NCT02963064Written as Humanized anti-CD117 Monoclonal Antibody (JSP191)
- JSP191 (briquilimab) in Subjects with LR-MDSTerminatedPhase 1Jasper Therapeutics, Inc.NCT05903274Written as JSP191
Given in every arm · 1 — briquilimab is usual care beside what is tested
Codes
What other systems call briquilimab · ClinicalTrials.gg INT017720
- UNII (FDA) QWX84D0DRCBRIQUILIMABOne source FDA
- NCI Thesaurus C174050BriquilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QWX84D0DRC | BRIQUILIMAB | One source FDA |
| NCI Thesaurus | C174050 | Briquilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.